Kapelios, Chris J., Naci, Huseyin, Vardas, Panos E. and Mossialos, Elias 
ORCID: 0000-0001-8664-9297
(2022)
Study design, result posting, and publication of late-stage cardiovascular trials.
European heart journal. Quality of care & clinical outcomes, 8 (3).
277 - 288.
ISSN 2058-1742
Abstract
AIMS: Pre-registration of study protocols in accessible databases is required for publication of study results in high-impact medical journals. Nonetheless, data on characteristics of clinical trials registered in these databases and their outcome, in terms of result reporting and publication are limited. METHODS AND RESULTS: We searched for interventional, late-phase cardiovascular disease (CVD) studies in adults registered in Clinicaltrials.gov. first posted after 1 January 2013 and completed up to 31 December 2018. Data on study design, result reporting, and publication were collected, and potential associations with a pre-defined set of explanatory factors were examined. In total, 250 CVD trials were included in the analysis. Of these, 193 (77.2%) were randomized studies, 99 (39.6%) open label designs, and 126 (50.4%) had industry as main sponsor. One hundred and seventy-nine trials (71.6%) evaluated the effect of drugs and 27 (10.8%) evaluated devices. The most common primary outcomes were non-clinical endpoints (76.0%), with only 17% of studies evaluating clinical endpoints. Industry-funded trials focused on patent-protected drugs and devices more often than non-industry-funded trials (72.0% vs. 30.6%, P < 0.001 and 55.0% vs. 26.3%, P = 0.033, respectively). Sixty-three studies (25.2%) had results posted on clinicaltrials.gov, and 116 (46.4%) had results published in the scientific literature. In multivariate analysis, industry sponsorship was statistically significantly associated with results posting [odds ratio (OR): 3.38; 95% confidence interval (CI): 1.56-7.30, P = 0.002] and publication (OR: 0.41; 95% CI: 0.23-0.75, P = 0.004). CONCLUSION: Among late-stage cardiovascular trials only one-fourth had results posted on clinicaltrials.gov and <50% had results published. Industry sponsors were more likely to invest in research on patent-protected drugs and devices than were non-industry sponsors. Industry-sponsored studies were more likely to have their results posted, but less likely to have their results published in the scientific literature.
| Item Type: | Article |
|---|---|
| Official URL: | https://academic.oup.com/ehjqcco |
| Additional Information: | © 2020 The Authors |
| Divisions: | Health Policy |
| Subjects: | R Medicine > R Medicine (General) |
| Date Deposited: | 25 May 2022 13:15 |
| Last Modified: | 17 Apr 2024 22:42 |
| URI: | http://eprints.lse.ac.uk/id/eprint/115198 |
Actions (login required)
 |
View Item |
